Raymond James & Associates’s RVL Pharmaceuticals plc Ordinary Shares RVLP Stock Holding History

Raymond James & Associates’s Portfolio RVLP Stock Details RVLP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-23,696	Closed	-$71	–	4095
2023 Q4	$71	Buy	+23,696	New	+$2.35K	﹤0.01%	3822
2021 Q3	–	Sell	-10,600	Closed	-$32K	–	4293
2021 Q2	$32K	Hold	10,600	–	–	﹤0.01%	3950
2021 Q1	$35K	Sell	10,600 -125	-1%	-$514	﹤0.01%	3880
2020 Q4	$44K	Buy	+10,725	New	+$61.8K	﹤0.01%	3636

Raymond James & Associates's RVLP Position: Q1 2024 in Review

Raymond James & Associates sold out of RVL Pharmaceuticals plc Ordinary Shares (RVLP) in Q1 2024, closing a stake of 23,696 shares — an estimated $71 sold.

Raymond James & Associates first reported a position in RVLP in Q4 2020 and held it in 4 quarters. The position peaked at $44K in Q4 2020. 0 funds tracked by Wall St. Rank hold RVLP as of Q1 2024.

Raymond James & Associates reported no remaining RVL Pharmaceuticals plc Ordinary Shares position as of Q1 2024 after selling out during the quarter.
Raymond James & Associates sold 23,696 RVL Pharmaceuticals plc Ordinary Shares shares in Q1 2024, an estimated $71.
Raymond James & Associates first reported a position in RVL Pharmaceuticals plc Ordinary Shares in Q4 2020 and held it in 4 quarters.
Raymond James & Associates's RVL Pharmaceuticals plc Ordinary Shares position peaked at $44K in Q4 2020.
0 funds tracked by Wall St. Rank held RVL Pharmaceuticals plc Ordinary Shares as of Q1 2024.

Based on Raymond James & Associates's 13F filing for Q1 2024, filed 22 Apr 2024.